Treatment of NSCLC patients with MetExon14 skipping mutation with and without co-occurring MET amplification, reflecting “real-world”1 setting FOSTER CITY, Calif., Dec. 04, 2023 Apollomics.
FOSTER CITY, Calif., Nov. 28, 2023 Apollomics Inc. , a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and.
Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the company reported fourth-quarter financial results.
Apollomics, Inc. (NASDAQ: APLM) has seen a significant surge in its shares, rising by ~20% at time of writing, accumulating a staggering 58% gain since November 21st, 2023. Surprisingly, there haven’t been any noticeable press releases or filings to explain this sudden valuation shift, so it’s prompted a closer examination on our end. Fortunately enough, […]